NCT02163070

Brief Summary

The purpose of the study is to evaluate the effect of vitamin E fortified whey drink on nutritional status, inflammatory markers and oxidative stress in hemodialysis patients

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
92

participants targeted

Target at P50-P75 for phase_2

Timeline
Completed

Started Sep 2013

Shorter than P25 for phase_2

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 1, 2013

Completed
6 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 1, 2014

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2014

Completed
9 days until next milestone

First Submitted

Initial submission to the registry

June 10, 2014

Completed
3 days until next milestone

First Posted

Study publicly available on registry

June 13, 2014

Completed
Last Updated

January 9, 2015

Status Verified

January 1, 2015

Enrollment Period

6 months

First QC Date

June 10, 2014

Last Update Submit

January 8, 2015

Conditions

Keywords

whey proteinmalnutritionoxidative stresshemodialysis

Outcome Measures

Primary Outcomes (2)

  • malnutrition (based on SGA assessment)

    2 months (8 weeks)

  • Malnutrition inflammation score

    2 months (8 weeks)

Secondary Outcomes (16)

  • serum interleukin-6

    2 months (8 weeks)

  • serum C-reactive protein

    2 months (8 weeks)

  • serum albumin

    2 months (8 weeks)

  • serum HDL-c

    2 months (8 weeks)

  • serum total cholesterol

    2 months (8 weeks)

  • +11 more secondary outcomes

Study Arms (4)

whey drink

EXPERIMENTAL

consumption of 220 milliliters of whey drink three times a week,

Dietary Supplement: whey drink,

whey drink fortified with vitaminE

EXPERIMENTAL

consumption of 220 milliliters of whey drink fortified with 400 milligrams of vitamin E three times a week,

Dietary Supplement: whey drink fortified with vitaminE

vitaminE

EXPERIMENTAL

consumption of 400 milligrams of vitamin E three times a week,

Dietary Supplement: vitamin E

D- control

NO INTERVENTION

control group: no intervention,

Interventions

whey drink,DIETARY_SUPPLEMENT

consumption of 220 milliliters of whey drink three times a week,

whey drink

consumption of 220 milliliters of whey drink fortified with 400 milligrams of vitamin E three times a week,

whey drink fortified with vitaminE
vitamin EDIETARY_SUPPLEMENT

consumption of 400 milligrams of vitamin E three times a week,

vitaminE

Eligibility Criteria

Age17 Years - 65 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • mean age of 17-65 years old;
  • having mild, moderate or severe malnutrition based on the SGA (subjective global assessment) assessment;
  • be dialyzed at least 2 times a week for 3 months

You may not qualify if:

  • hospitalization in the last month;
  • active infection;
  • using immunosuppressant drugs or multi-vitamins;
  • pregnancy, consuming whey or soy products

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (1)

  • Mah JY, Choy SW, Roberts MA, Desai AM, Corken M, Gwini SM, McMahon LP. Oral protein-based supplements versus placebo or no treatment for people with chronic kidney disease requiring dialysis. Cochrane Database Syst Rev. 2020 May 11;5(5):CD012616. doi: 10.1002/14651858.CD012616.pub2.

MeSH Terms

Conditions

Renal Insufficiency, ChronicMalnutrition

Interventions

Vitamin E

Condition Hierarchy (Ancestors)

Renal InsufficiencyKidney DiseasesUrologic DiseasesFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesMale Urogenital DiseasesChronic DiseaseDisease AttributesPathologic ProcessesPathological Conditions, Signs and SymptomsNutrition DisordersNutritional and Metabolic Diseases

Intervention Hierarchy (Ancestors)

BenzopyransPyransHeterocyclic Compounds, 1-RingHeterocyclic CompoundsHeterocyclic Compounds, 2-RingHeterocyclic Compounds, Fused-Ring

Study Officials

  • Mohammad Hassan Eftekhari, professor

    Shiraz University of Medical Sciences

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
phase 2
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
professor. PhD

Study Record Dates

First Submitted

June 10, 2014

First Posted

June 13, 2014

Study Start

September 1, 2013

Primary Completion

March 1, 2014

Study Completion

June 1, 2014

Last Updated

January 9, 2015

Record last verified: 2015-01